Polymorphonuclear leucocyte function and previous yersinia arthritis: enhanced chemokinetic migration and oxygen radical production correlate with the severity of the acute disease.

Koivuranta-Vaara, P; Leirisalo‐Repo, Marjatta; Repo, Heikki

doi:10.1136/ard.46.4.307

Cited by 15 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 We have also previously shown that PMN of the patients who have sequelae tend to show increased migration.5 These findings support the view that among patients with reactive arthritis there are subgroups with hyperreactive neutrophils, which may contribute to the development of severe inflammatory symptoms. Clinical studies also provide evidence of subgroups: according to the 10 year follow up study about 30% of patients with yersinia arthritis develop sacroiliitis, even ankylosing spondylitis.38 It is interesting that purified PMN of patients with ankylosing spondylitis show increased chemotactic responses to ZTS39 4 but not to FMLP,4' both under agarose and in the filter.…”

Section: Discussionsupporting

confidence: 61%

Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.

Leirisalo‐Repo

Lauhio

Repo

1990

Annals of the Rheumatic Diseases

Self Cite

View full text Add to dashboard Cite

Patients and methods PATIENTSWe studied 12 patients with acute reactive arthritis, who presented with acute oligoarthritis or polyarthritis mainly affecting the lower extremities. The patients were treated at the Helsinki University Central Hospital or at the Aurora Hospital, Helsinki. Table 1 shows the characteristics of the patients. At the time when the synovial fluid and blood samples were taken the patients were treated with non-steroidal antiinflammatory agents. Healthy HLA-B27 negative members of the hospital and laboratory staff served as controls. A patient and a control formed a fixed pair which was tested at the acute phase of the disease, one month later, and at six months after recovery. Two patients were tested at the acute phase only; one was not reached for subsequent testing and the other with acute colitis later developed Crohn's disease. To study the relation between severity of inflammation and phagocyte function the patients were divided into two groups: those with severe acute disease (n= 5) and those with mild acute disease (n=7, table 1). CELLSAll the patients had effusion of the knee joint, which was aspirated. The leucocyte counts in the synovial fluid varied from 4x 109 to 12 4x 109/1 (mean 7 7x 109/1). The proportion ofPMN varied

show abstract

Section: Discussionsupporting

confidence: 61%

Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.

Leirisalo‐Repo

Lauhio

Repo

1990

Annals of the Rheumatic Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Sulfasalazine in the treatment of ankylosing spondylitis

Nissilä

Lehtinen

Leirisalo‐Repo

et al. 1988

Arthritis & Rheumatism

113

View full text Add to dashboard Cite

Eighty-five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine ( 5 3 gm/day, mean 2.5) or placebo for 26 weeks. There was a statistically significant improvement, compared with baseline, in most of the clinical variables in patients receiving the active drug. Laboratory parameters (erythrocyte sedimentation rate, Creactive protein, IgG, IgM, and IgA) also improved during the active treatment, suggesting a beneficial effect of sulfasalazine on AS. At the end of the treatment, significant differences between the sulfasalazine and placebo groups were observed in morning stiffness, chest expansion, erythrocyte sedimentation rate, and in all immunoglobulin classes. Two patients in each treatment group discontinued the trial because of side effects. Enteric-coated sulfasalazine seemed to be effective and well tolerated in patients with active AS.Ankylosing spondylitis (AS) is one of the HLA-B27-associated diseases (1). In some of these diseases, infection is considered to be an etiologic factor.To date, however, the role of infection in the etiology of AS has not been confirmed. The association beFrom the Rheumatism Foundation

show abstract

Polymorphonuclear leukocyte chemiluminescence response in HLA-B27 positive and negative arthritic patients

Tertti

1989

Rheumatol Int

View full text Add to dashboard Cite

The polymorphonuclear leukocyte (PMN) chemiluminescence (CL) response to opsonized zymosan reflecting the C3b/C3bi-receptor-mediated PMN respiratory burst activation was studied in 99 arthritic patients typed for the HLA-B27 antigen. The results indicate that the B27 antigen per se is not associated with disturbances in PMN CL response. However, the erythrocyte sedimentation rate showed a correlation with CL, suggesting that the activity of arthritic disease may affect the PMN CL response.

show abstract

Polymorphonuclear leucocyte function and previous yersinia arthritis: enhanced chemokinetic migration and oxygen radical production correlate with the severity of the acute disease.

Cited by 15 publications

References 20 publications

Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.

Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.

Sulfasalazine in the treatment of ankylosing spondylitis

Polymorphonuclear leukocyte chemiluminescence response in HLA-B27 positive and negative arthritic patients

Contact Info

Product

Resources

About